Updates from day 3 of the Huntington’s Disease Therapeutics Conference: huntingtin protein - and lowering it
DNA takes centre stage for day 2 of the Huntington's Disease Therapeutics Conference in Palm Springs
Our daily roundup of the science presented at the 2018 HD Therapeutics Conference in Palm Springs
A surprising new paper sheds light on the role of the HD gene early in development. Should we worry?
Promising results in mice provide renewed optimism for mGluR5 antagonists
In a Q&A coordinated by the UK HD Association, Dr Ed Wild answers questions on the recently-announced trial
Amazing news from Ionis and Roche! HTTRx drug successfully lowers harmful huntingtin protein in spinal fluid
CRISPR genome editing just got an off-switch. We cut through the hype to explore the technology in HD
Can we test drugs to delay or prevent the onset of Huntington's disease? New research suggests it's possible
Ionis says its trial of HTTRx, intended to lower huntingtin protein, is fully recruited and plans to extend it
Completely removing normal huntingtin in adults may disrupt healthy brain function, a recent study suggests.